BioAlliance Pharma SA said today it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate, at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30.
Dais Analytic Corporation announced today its nanotechnology ConsERV energy recovery ventilation product has been recognized with the prestigious first place award for "Innovative Ventilation, Air Conditioning Design, and Energy Efficiency" from the American Society of Heating, Refrigeration and Air Conditioning Engineers.
Industrial Nanotech, Inc. announced today that Pioneer Builders, an exclusive distributor for the Company's patented product line, will begin applying Nansulate to the buildings housing electronic circuits for a major telecommunications company.
Electric car pioneer ZAP today announced that it has acquired the exclusive American distribution license from CCT Power Company of Temple City, California to market batteries from Advanced Battery Technologies, Inc. for its Portable Energy lines.
The Canadian scientists and entrepreneurs who are developing exciting micro- and nanotechnology innovations are among the experts headlining the CMC Microsystems Annual Symposium on October 18, 2007 in Ottawa, Ontario.
With nanotechnology industry advancing rapidly RNCOS released a report titled 'The World Nanotechnology Market (2006)', provides an updated and detailed overview of the Nanotechnology market worldwide.
Piezo motor specialist PI (Physik Instrumente) L.P. offers a new family of ultrasonic piezo-motor-driven linear stages: Models M-663, M-664 and M-682 provide travel ranges to 50 mm in a very compact package.
The Do-Coop Technologies team looks forward to the opportunity of an open dialogue of the future directions in the study of the biochemical composition of water with co-participants at the upcoming Scientific Water Meeting in Vermont.
Abraxis BioScience, Inc. today announced that ABRAXANE powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel), has received a positive opinion in favor of approval from the European Committee for Human Medicinal Products for the treatment of metastatic breast cancer in women who have failed therapy in the first-line setting.
Ultratech, Inc. today announced unaudited results for the three-month and nine-month periods ended September 29, 2007. The company's net loss for the third quarter of 2007 was $0.9 million or $0.04 per share on net sales of $25.2 million.
VeruTEK Technologies, Inc. announced the completion of a private placement offering whereby the Company sold approximately 1.34 million shares of its common stock plus warrants to purchase approximately 2.7 million additional shares of common stock.